FAM172BP

Across TCGA pan-cancer cohorts, FAM172BP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM172BP data layer compared with 22 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher FAM172BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM172BP expression acts as an unfavorable survival marker.

MESO and UCEC are the cancer types where FAM172BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.018	0.559	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM172BP–MESO (OS)

Open the MESO breakdown →